Advik Laboratories Ltd - 531686 - Statement Of Investor Complaints For The Quarter Ended 30Th September, 2025
Awaiting price reaction for this filing.
MPS Pharmaa Limited (formerly Advik Laboratories Ltd) has filed its quarterly investor complaints report for Q2 FY26 (July–September 2025) with BSE, as required under SEBI Regulation 13(3). The company reported zero investor complaints pending at the start of the quarter, zero received during the quarter, zero disposed of, and zero unresolved at the end of the quarter. The filing was signed by Company Secretary Pooja Chuni on 13 October 2025. This is a routine compliance disclosure with no operational or financial implications.
This is a standard regulatory filing with no impact on shareholders or stock price. Zero complaints reflect clean investor servicing for the quarter, but this is a routine disclosure required of all listed companies.